.png)
Chair
ASN Committee on Advocacy and Science Policy (CASP)
Kensington, Maryland, United States
Christine Lewis Taylor, PhD, began her career in 1986 as a scientist with the Food and Drug Administration (FDA). In 2000 she was named Director of the Office of Nutritional Products, Labeling and Dietary Supplements at FDA's Center for Food Safety and Applied Nutrition. In this capacity, she oversaw a staff of more than 50 scientists who were responsible for research, regulation and enforcement related to nutrition issues and dietary supplements. During this time she also served as lead of the U.S. delegation to the United Nations-sponsored Codex Alimentarius Committee on Nutrition Labeling. From 2004 to 2006 FDA assigned Dr. Taylor to the World Health Organization where she worked on the topic of approaches for determining dietary supplement safety. Following her retirement from the agency, Dr. Taylor was named a Scholar in the Institute of Medicine at The National Academies in Washington DC where she was Study Director from 2006 to 2010 for four projects including an evaluation of the process for setting Dietary Reference Intakes, consensus recommendations for the standards for school lunch, identification of strategies for reducing sodium in the diet, and an evaluation of the recommended intakes for vitamin D and calcium. Dr. Taylor served as a contracting scientist for the Office of Dietary Supplements at the National Institutes of Health from 2011 to 2017 where she conducted research and was responsible for developing workshops and conferences targeted to a range of nutrition topics. Currently, Dr. Taylor serves as Chair of ASN’s Committee on Advocacy and Science Policy.
Thursday, June 16, 2022
12:00 PM – 1:30 PM ET
Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.
Thursday, September 22, 2022
12:00 PM – 1:30 PM ET
Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.
Thursday, September 22, 2022
12:05 PM – 12:20 PM ET
Disclosure(s): No relevant financial relationship(s) with ineligible companies to disclose.